Psilocybin, MDMA and ibogaine are not FDA-approved for PTSD, depression or addiction and are Schedule I federally. The lawful US route to them is authorized research, including VA-funded studies.
At The Psychedelic Journal, we track scheduling, agency action and research news so readers can tell investigational studies from lawful care.
Can Veterans Get Psychedelic Therapy?
No psychedelic (psilocybin, MDMA, ibogaine or LSD) is FDA-approved for PTSD, depression or addiction as of September 30, 2026, and the VA does not provide Schedule I psychedelics as care. Access falls into three categories: No psychedelic has an approved indication, so investigational access occurs through clinical research, and state-regulated psilocybin programs are not medical care.
Three categories of access
First, none of psilocybin, MDMA or ibogaine is an approved treatment. The Food and Drug Administration (FDA) has not approved psilocybin, MDMA, or ibogaine for post-traumatic stress disorder (PTSD), depression, or substance use disorders. Because these compounds lack federal marketing authorization, the VA does not provide them as care.
Second, investigational access occurs through clinical research. Clinical trials of these compounds proceed under FDA oversight and other applicable federal requirements. Veterans who meet a study's eligibility criteria may be able to take part within that study's protocol.
Third, state-regulated programs operate independently of the federal healthcare system. Oregon and Colorado run administrative programs allowing adults to access psilocybin adult-access programs under state law. These state initiatives do not constitute medical treatment, do not treat mental health conditions, and have no affiliation with VA healthcare benefits.
Approved, Investigational and State-Regulated: The Difference
The table shows where each compound stands.
| Compound | Federal Status | FDA Approval | VA Role |
|---|---|---|---|
| Psilocybin | Schedule I | No approved indication | Research only |
| MDMA | Schedule I | No approved indication | Research only |
| Ibogaine | Schedule I | No approved indication | No VA care; ARPA-H awards fund groundwork and do not open a trial |
| Esketamine | Schedule III | Approved for treatment-resistant depression (under REMS) | Ask your VA provider |
On November 12, 2026, the Advanced Research Projects Agency for Health (ARPA-H) announced awards of up to $4.9 million over five years for groundwork toward future ibogaine Investigational New Drug (IND) applications. The announcement cites serious mental illness, including post-traumatic stress disorder (PTSD), and challenges facing U.S. Veterans. ARPA-H's November 12 announcement says no current IND exists to legally and safely study ibogaine as a psychiatric treatment, so the awards have not opened an authorized ibogaine PTSD trial for veterans to join. None of the ARPA-H, FDA, or Texas Health and Human Services Commission (HHSC) pages reviewed on November 14, 2026 describes VA ibogaine care. 21 CFR 1308.11 lists ibogaine in Schedule I. No FDA approval of ibogaine appears in the sources reviewed on November 14, 2026. For the scope of the awards, see what the awards fund and do not authorize.
Federal law classes Schedule I substances such as psilocybin, MDMA, and ibogaine as having a high potential for abuse and no currently accepted medical use.
Esketamine is different. The FDA approved esketamine nasal spray for treatment-resistant depression subject to a Risk Evaluation and Mitigation Strategy (REMS). Ketamine is a Schedule III compound prescribed off-label in specialized clinics. Veterans should ask their individual VA provider about the availability and clinical criteria for esketamine, as covered in our guide to best ketamine therapy for veterans and our overview of ketamine.
What the VA Is Doing
DAV reports the VA's involvement is research. In January 2024, the VA announced a request for applications for research on psychedelic compounds, such as MDMA and psilocybin, combined with psychotherapy for PTSD and depression, as reported by Disabled American Veterans (DAV).
DAV notes that these compounds are controlled substances, tightly restricted under federal law, and that research on them may be conducted with appropriate regulatory approvals from the FDA and the DEA.
In 2026, DAV also applauded the VA for launching a clinical trial evaluating MDMA-assisted therapy for veterans diagnosed with PTSD and alcohol use disorder. This is a research trial, not an approved therapy or a VA benefit. Nothing in DAV's reporting describes MDMA as routine VA care.
Veterans seeking background on the clinical trial literature for service-related trauma can consult our guide to psychedelic therapy for PTSD. For the compounds themselves, see our review of MDMA and our guide to psilocybin.
What the 2026 Executive Order Changes and Does Not Change
Executive Order 14401 directs federal agencies to accelerate research pathways for serious mental illness treatments but leaves federal drug scheduling unchanged. President Donald Trump signed Executive Order 14401, titled "Accelerating Medical Treatments for Serious Mental Illness," on April 18, 2026. The official document was published in the Federal Register on April 22, 2026, as Federal Register document 2026-07907.
The order instructs executive departments and federal agencies to accelerate review processes and improve access pathways for treatments intended for serious mental illness.
The executive order does not reschedule any psychedelic substance under federal law. Psilocybin, MDMA, dimethyltryptamine (DMT), and ibogaine remain listed under Schedule I of the Controlled Substances Act at 21 U.S.C. § 812.
On April 20, 2026, DAV National Commander Coleman Nee issued a statement applauding the executive order as a step toward accelerating clinical research and expanding access pathways for veterans. Nee said DAV will keep pressing for public policies that ensure promising therapies are thoroughly studied, responsibly implemented, and made accessible.
Commander Nee's statement reflects the advocacy objectives of a veterans organization. His remarks do not change the statutory classification of controlled substances or create legal authority for clinicians to administer Schedule I drugs outside research trials. A full legal analysis of the directive appears in our guide to the Trump psychedelics executive order.
What DAV Announced
In 2026 DAV launched an educational resource and announced a partnership with Americans for Ibogaine. Disabled American Veterans (DAV) is a congressionally chartered nonprofit organization founded in 1920 with nearly 1 million members. DAV represents veteran interests through legislative advocacy rather than direct medical care or drug regulation.
DAV's resource and resolution
In 2026, DAV announced the launch of an online resource dedicated to psychedelic-assisted therapies for service-connected mental health conditions. In its official press release, DAV noted that a growing number of veterans seek alternative treatments after exhausting traditional clinical options. DAV observed that clinical researchers are advancing studies on plant medicines like psilocybin, ibogaine, and MDMA during a period when domestic legal access remains limited.
DAV also emphasized that many veterans travel abroad, often at significant personal risk and cost, for these treatments. In response, DAV said it champions continued rigorous research while stressing the necessity of patient safety, professional oversight, and evidence-based clinical care.
The organization's Psychedelics for Veterans Health Care page records that DAV adopted a formal resolution at its 2024 national convention in Phoenix. The resolution encourages the VA to research and make available any psychedelic compound for treatment following FDA approval. DAV explicitly emphasizes that current scientific studies remain in early stages and that researchers must conduct further investigations to establish long-term safety and clinical efficacy.
In a separate 2026 announcement from Erlanger, Kentucky, DAV and Americans for Ibogaine announced a partnership on education, public awareness, research, and legislative advocacy. DAV stated in the release that ibogaine is not approved for medical use at the federal level, even as state-level research initiatives and policy discussions advance. The partnership intends to mobilize DAV members to advocate for evidence-based ibogaine research in state legislatures across the country.
Ibogaine remains a Schedule I controlled substance with distinct medical risks. We do not evaluate ibogaine as safe or effective on this site; readers can review our guide to ibogaine for safety concerns and examine our analysis of where ibogaine is legal.
Risks and Why Travel Abroad Is Not a Shortcut
Traveling outside the United States for psychedelic treatment carries risk. DAV reports that veterans traveling overseas for alternative treatments often do so at significant personal risk and cost. At The Psychedelic Journal, we do not recommend, rank, source, or facilitate international psychedelic retreats or foreign medical clinics.
DAV names significant personal risk and cost, and we do not recommend treatment abroad.
Some medications may interact with psychedelics, so a prescriber should review any plan.
Veterans must never discontinue, reduce, or alter prescribed psychiatric medications without the direct supervision of their prescribing clinician. Veterans can explore potential pharmacological conflicts using our medication safety checker and read our detailed guide on psychedelic medication safety.
Check current state law with our legal status tool or our guide on where MDMA is legal.
Where to Go Next
Veterans can look for active studies with our clinical trial finder. Search active clinical protocols using our clinical trial finder and evaluate the medical literature in our overview of psychedelic therapy for PTSD. To verify local statutory frameworks and scheduling policies across individual jurisdictions, visit our state-by-state legal status tool. If you or a veteran you know is facing an immediate mental health crisis, access immediate support through our crisis resources page. Always consult a licensed physician and a qualified attorney before considering any decision involving psychedelic therapy for veterans.
General information only. The Psychedelic Journal does not provide medical or legal advice. Consult a licensed physician and qualified legal counsel regarding your specific circumstances.